It is arguable that intratumoral treatment with IL-2 may have diverse effects on the tumor microenvironment, i.e., not only induction of CD8+ cytotoxic T cells or NK cells but also induction of regulatory T cells (Tregs) [20,21]. The gene discussed is CD8A; the disease is neoplasm.